North America Biopharmaceuticals Market Poised for Strong Growth, Driven by Rare Disease Treatments
The North America biopharmaceuticals market, valued at 151.22 billion in 2022, is projected to surge to 151.22 billion in 2022, Is projected to surge to 315.74 billion by 2028, growing at a 13.1% CAGR during the forecast period. A key driver of this expansion is the increasing focus on developing therapies for rare diseases, which affect millions across the region.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 – https://www.businessmarketinsights.com/sample/BMIRE00028630
Rising Demand for Rare Disease Treatments
According to the National Institutes of Health (NIH), approximately 30 million Americans (10% of the population) suffer from one of 7,000 known rare diseases. Developing treatments for these conditions presents significant scientific and operational hurdles due to complex disease biology. Despite these challenges, biopharmaceutical companies in North America are pioneering innovative therapies, leveraging advances in biotechnology to address unmet medical needs.
In the past decade, the U.S. FDA has approved 350 orphan drugs, many targeting conditions with limited or no existing treatment options. One example is transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and fatal cardiovascular disease with a median survival of just 2.5–3.5 years if untreated. Breakthrough therapies are transforming outcomes for patients with such conditions.
Cutting-Edge Developments in Biopharmaceuticals
Companies like Ultragenyx Pharmaceutical Inc. are at the forefront of rare disease research. In December 2021, Ultragenyx initiated clinical trials for UX053, an investigational mRNA therapy designed to treat Glycogen Storage Disease Type 3 (GSD3), a severe genetic disorder. Unlike traditional approaches, UX053 delivers large genes to target cells, enabling high protein expression uniformity. The therapy is being tailored to individual patient needs through adjustable dosing and frequency.
Market Outlook
With continued advancements in mRNA technology, gene therapy, and personalized medicine, the North America biopharmaceuticals market is set for robust growth. Increased FDA approvals, coupled with strong investment in orphan drug development, will further propel the industry, offering hope to millions of patients with rare and life-threatening conditions.
Overview of the North America Biopharmaceuticals Market
The North America biopharmaceuticals market encompasses the US, Canada, and Mexico, with significant growth driven by factors such as the increasing incidence of cancer, ongoing product innovations, and advancements in biopharmaceutical technology. This industry stands at the forefront of medical research, offering transformative potential in the treatment of high-cost and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C.
In the US, the growing prevalence of chronic diseases and rising investments in research and development (R&D) are key drivers of market expansion. The country leads global R&D investment and innovation, with over 3,400 drugs in clinical development as of 2020—nearly half of the estimated 8,000 drugs in development worldwide. Among these, approximately 1,100 drugs target various forms of cancer.
Beyond its impact on healthcare, the biopharmaceutical industry plays a crucial role in the US economy, generating both direct and indirect economic activity. In 2018, pharmaceutical and medical manufacturing contributed 0.95% of private-sector value added, while biotech R&D facilities accounted for an additional 0.23%.
According to the Centers for Disease Control and Prevention (CDC), coronary artery disease remains the most prevalent form of heart disease, affecting approximately 20.1 million US adults aged 20 and older as of July 2022. Furthermore, CDC data reveals that someone in the US experiences a heart attack every 40 seconds, with nearly 805,000 cases occurring annually.
Given these factors, the North America biopharmaceuticals market is poised for significant growth in the coming years.
North America Biopharmaceuticals: Strategic Insights
The North American biopharmaceutical industry is a dynamic and evolving landscape shaped by emerging trends, key players, and regional complexities. Data-driven strategic insights provide a competitive edge by identifying untapped market segments, optimizing value propositions, and anticipating industry shifts.
By leveraging analytics, stakeholders—including investors, manufacturers, and policymakers—can proactively navigate market changes, capitalize on growth opportunities, and mitigate risks. A forward-looking approach is crucial for long-term success, ensuring businesses remain agile and resilient in an increasingly competitive environment.
Ultimately, well-informed strategic decisions drive profitability and position industry players for sustained success in North America’s biopharmaceutical sector.
North America Biopharmaceuticals Regional Insights
The geographic scope of the North America Biopharmaceuticals refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
North America Biopharmaceuticals Market Segmentation
| Category | Segments |
| By Product Type | Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, Others |
| By Application | Oncology, Inflammatory & Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, Others |
| By Country | United States, Canada, Mexico |
| Key Market Players | AbbVie Inc., AGC Biologics AS, Amgen Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co., Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc., WuXi Biologics Inc. |
About Us: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio
Akshay
Senior Market Research Expert at Business Market Insights
